| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | 0.097 | 0.01 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.16 | 0.01 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.01 |
| mRNA | ZSTK474 | GDSC1000 | pan-cancer | AAC | -0.086 | 0.01 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | -0.088 | 0.01 |
| mRNA | AZD7762 | GDSC1000 | pan-cancer | AAC | 0.09 | 0.02 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | MS-275 | CTRPv2 | pan-cancer | AAC | -0.091 | 0.02 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.12 | 0.02 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.083 | 0.02 |